Researchers have taken a major step toward a landmark male contraceptive by successfully completing the Phase 1a human safety trial for YCT‑529, the first hormone-free oral birth control pill for men.

The drug was well tolerated across all doses, showing no adverse effects on heart rate, inflammatory markers, reproductive hormones (such as testosterone, FSH, or LH), sexual desire, or mood. Pharmacokinetic data confirmed it reached effective levels in the body, with no significant impact from food intake—signaling a strong safety and tolerability profile.

This innovation is especially significant because women currently shoulder most of the financial and health-related burdens of contraception. If future trials confirm its effectiveness and reversibility, YCT-529 could offer couples a new, equitable way to share responsibility for birth control.

Source: Scientific American

https://www.scientificamerican.com/article/male-birth-control-pill-yct-529-passes-human-safety-test